Does Rallies show 13F holders for VKTX?

Yes. Rallies tracks hedge fund and 13F ownership data for VKTX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is VKTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VKTX. It does not provide personalized investment advice.

VKTX (Viking Therapeutics) Stock Analysis - Hedge Fund Holdings

Viking Therapeutics (VKTX) is a publicly traded Healthcare sector company. As of May 20, 2026, VKTX trades at $29.45 with a market cap of $3.33B and a P/E ratio of -9.16. VKTX moved +3.56% today. Year to date, VKTX is -8.40%; over the trailing twelve months it is +2.69%. Its 52-week range spans $18.92 to $81.73. Analyst consensus is strong buy with an average price target of $95.63. Rallies surfaces VKTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns VKTX stock?

Hedge funds tracked by Rallies that own VKTX include Viking Global, Blackbarn Capital, Duquesne Family, Soros Fund, and Bridgewater Associates. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Viking Therapeutics.

VKTX Key Metrics

Key financial metrics for VKTX
Metric	Value
Price	$29.45
Market Cap	$3.33B
P/E Ratio	-9.16
EPS	$-3.19
Dividend Yield	0.00%
52-Week High	$81.73
52-Week Low	$18.92
Volume	1.41M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-359.64M
Gross Margin	0.00%

Top Hedge Funds Holding VKTX

Viking Global holds 721.93K shares of VKTX, changed -46.70% as of Sep 30, 2024.
Blackbarn Capital holds 621.45K shares of VKTX, changed +12.99% as of Mar 31, 2026.
Duquesne Family holds 549.29K shares of VKTX, changed +0.00% as of Jun 30, 2025.
Soros Fund holds 90.00K shares of VKTX, changed +0.00% as of Dec 31, 2025.
Bridgewater Associates holds 71.23K shares of VKTX, changed -31.29% as of Mar 31, 2026.

Latest VKTX News

Viking Therapeutics to Present Phase 2 Weight Loss Data and Phase 3 Enrollment at ECO 2026 — May 5, 2026
Ends Q1 with $603 M Cash, Enrolls 5,500 in Phase 3 VK2735 Trials — Apr 29, 2026
Jefferies Reaffirms Buy as Viking Therapeutics Gains 16.5%; VK2735 Oral Study Slated — Mar 12, 2026
Viking Therapeutics Shares Drop 1.96%, Q1 EPS Forecast at -$1.01 — Mar 5, 2026
Viking Therapeutics Shares Surge Over 10% After Competitor’s Obesity Drug Miss — Feb 23, 2026

Recent VKTX Insider Trades

Aubuchon Neil William bought 4.47K (~$149.91K) on Mar 10, 2026.
ZANTE GREG sold 31.96K (~$1.03M) on Jan 5, 2026.
ZANTE GREG sold 13.90K (~$464.02K) on Jan 5, 2026.

VKTX Analyst Consensus

10 analysts cover VKTX: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $95.63.

Common questions about VKTX

Who owns VKTX stock?: Hedge funds tracked by Rallies that own VKTX include Viking Global, Blackbarn Capital, Duquesne Family, Soros Fund, and Bridgewater Associates. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Viking Therapeutics.
Does Rallies show 13F holders for VKTX?: Yes. Rallies tracks hedge fund and 13F ownership data for VKTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is VKTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VKTX. It does not provide personalized investment advice.